A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia
The DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index.
Abstract
Purpose To assess the efficacy of fluoxetine in the treatment of patients with fibromyalgia.Subjects and methods Sixty outpatients (all women, aged 21-71 years) with fibromyalgia were randomly assigned to receive fluoxetine (10-80 mg/d) or placebo for 12 weeks in a double-blind, parallel-group, flexible-dose study. The primary outcome measures were the Fibromyalgia Impact Questionnaire total score (score range, 0 [no impact] to 80) and pain score (score range, 0-10). Secondary measures included the McGill Pain Questionnaire, change in the number of tender points, and total myalgic score.Results In the intent-to-treat analysis, women who received fluoxetine (mean [+/- SD] dose, 45 +/- 25 mg/d) had significant (P = 0.005) improvement in the Fibromyalgia Impact Questionnaire total score compared with those who received placebo, with a difference of -12 (95% confidence interval [CI]: -19 to -4). They also had significant (P = 0.002) improvement in the Fibromyalgia Impact Questionnaire pain score (difference, -2.2 [95% CI: -3.6 to -0.9]), as well as in the Fibromyalgia Impact Questionnaire fatigue (P = 0.05) and depression (P = 0.01) scores and the McGill Pain Questionnaire (P = 0.01), when compared with subjects who received placebo. Although counts for the number of tender points and total myalgic scores improved more in the fluoxetine group than in the placebo group, these differences were not statistically significant.Conclusions In a 12-week, flexible-dose, placebo-controlled trial, fluoxetine was found to be effective on most outcome measures and generally well tolerated in women with fibromyalgia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although improvements in VAS and FIQ scores were present after 4 weeks of treatment, there was no significant change in the number of tender points or tender point pain threshold, which is supported by other studies.2,23”
From Nabilone for the treatment of pain in fibromyalgia. (2008) · cites this paper as [2]
In the citing paper
“Comparing the baseline FIQ scores in our study to some recent studies that used the FIQ, our subjects scored on average 12 to 22 points higher,2,5,30 indicating their quality of life was more severely affected by fibromyalgia.23”
From Nabilone for the treatment of pain in fibromyalgia. (2008) · cites this paper as [2]
In the citing paper
“The significant drop in the VAS (−2.04, P < .02) in our treatment group was similar to those of other drug trials, which ranged from 1.2 to 2.2.2,5,17”
From Nabilone for the treatment of pain in fibromyalgia. (2008) · cites this paper as [2]
In the citing paper
“Our finding of a significant drop in the FIQ score (−12.07, P < .02) was also similar to other drug trials whose drop in FIQ score ranged from 5.53 to 15.8.2,3,5,17,30”
From Nabilone for the treatment of pain in fibromyalgia. (2008) · cites this paper as [2]
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
The american college of rheumatology 1990 criteria for the classification of fibromyalgia
Wolfe, F., Smythe, H. A., Yunus, M. B., Bennett, R. M., Bombardier, C., Goldenberg, D. L., Tugwell, P., Campbell, S. M., Abeles, M., Clark, P., et al. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780330203 · Cited by 9,563
The McGill Pain Questionnaire: Major properties and scoring methods
Melzack, R. (1975) · Pain · doi:10.1016/0304-3959(75)90044-5 · Cited by 6,845
Wolfe, F., Ross, K., Anderson, J., Russell, I. J., & Hebert, L. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380104 · Cited by 2,416
(1991) · PubMed · Cited by 1,837
Fischer, A. A. (1987) · Pain · doi:10.1016/0304-3959(87)90089-3 · Cited by 958
Comorbidity of fibromyalgia with medical and psychiatric disorders
Hudson, J. I., Goldenberg, D. L., Pope, H. G., Keck, P. E., & Schlesinger, L. (1992) · The American Journal of Medicine · doi:10.1016/0002-9343(92)90265-d · Cited by 492
Self-citationAntidepressant Treatment of Fibromyalgia: A Meta-Analysis and Review
Arnold, L. M., Keck, P. E., & Welge, J. A. (2000) · Psychosomatics · doi:10.1176/appi.psy.41.2.104 · Cited by 448
Self-citationGoldenberg, D., Mayskiy, M., Mossey, C., Ruthazer, R., & Schmid, C. (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780391111 · Cited by 420
Treatment of fibromyalgia with antidepressants: A meta-analysis
O’Malley, P. G., Balden, E., Tomkins, G., Santoro, J., Kroenke, K., & Jackson, J. L. (2000) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2000.06279.x · Cited by 340
Research works printed but not linked: 1
- Okifuji, 1997, A standardized manual tender point survey, J Rheumatol, 24, 377
Cited by
Fibromyalgia: A Clinical Review
Clauw, D. J. (2014) · JAMA · doi:10.1001/jama.2014.3266 · Cited by 1,674
Management of fibromyalgia syndrome
Goldenberg, D. L. (2004) · JAMA · doi:10.1001/jama.292.19.2388 · Cited by 850
“However, a flexible placebo-controlled dose study of fluoxetine ( 80 mg/d) demonstrated significant efficacy in 60 women with fibromyalgia.(45) Improvement was noted on FIQ total score as well as subscores for pain, fatigue, and depression.”
BackgroundEULAR evidence-based recommendations for the management of fibromyalgia syndrome
Carville, S. F., Arendt-Nielsen, S., Bliddal, H., Blotman, F., Branco, J. C., Buskila, D., Da Silva, J. A. P., Danneskiold-Samsøe, B., Dincer, F., Henriksson, C., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.071522 · Cited by 752
Arnold, L. M., Lu, Y., Crofford, L. J., Wohlreich, M., Detke, M. J., Iyengar, S., & Goldstein, D. J. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20485 · Cited by 624
“of 120 mg/day was selected based on results of a previous clinical trial of fibromyalgia suggesting that patients might respond better to higher doses of antidepressants (16).”
MethodResultSelf-citationBennett, R. M. (2005) · PubMed · Cited by 726
Metadata
- Authors
- Arnold, L. M., Hess, E. V., Hudson, J. I., Welge, J. A., Berno, S. E., & Keck, P. E.
- Affiliations
- McLean Hospital (US)
- Harvard University (US)
- Corresponding author
- Arnold, Lesley M
- Venue
- The American Journal of Medicine
- Publisher
- Elsevier BV
- Published
- 2002-02
- Volume
- 112
- Issue
- 3
- Pages
- 191-197
- ISSN
- 0002-9343 (ISSN-L)
- OpenAlex
- W2048628544
- Cited by
- 261
- References
- 28
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 5 · 2023: 4 · 2022: 3 · 2021: 5 · 2020: 3 · 2019: 2 · 2018: 5 · 2017: 5 · 2016: 5 · 2015: 7 · 2014: 7 · 2013: 17 · 2012: 16
- FWCI
- 10.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The American Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Fibromyalgia and Chronic Fatigue Syndrome Research
- Health Sciences › Health Professions › Physical Therapy, Sports Therapy and Rehabilitation › Myofascial pain diagnosis and treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Psychosomatic Disorders and Their Treatments
- Keywords
- fluoxetine, fibromyalgia, women, selective serotonin reuptake inhibitors, pain, fatigue, depression, tender points, Fibromyalgia Impact Questionnaire, McGill Pain Questionnaire, drug efficacy, tolerability
- MeSH terms
- Adult, Aged, Double-Blind Method, Educational Status, Female, Fibromyalgia, Fluoxetine, Humans, Middle Aged, Pain Measurement, Surveys and Questionnaires, Treatment Outcome, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. https://app.cochat.ai/papers/10.1016/s0002-9343(01)01089-0
- The paper
- Arnold, L. M., Hess, E. V., Hudson, J. I., Welge, J. A., Berno, S. E., & Keck, P. E. (2002). A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. The American Journal of Medicine. https://doi.org/10.1016/s0002-9343(01)01089-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.